Health Condition 1: B258- Other cytomegaloviral diseases
Conditions
Interventions
None listed
Sponsors
SERB DST
Eligibility
Inclusion criteria
Inclusion criteria: All consecutive mechanically ventilated (at least >72h) adult septic patients (non-immuno compromised) with CMV seropositive status will be considered for inclusion in the study.
Exclusion criteria
Exclusion criteria: 1.Consent not given. 2.Expected survival 3.Use of antiviral agent cidofovir, foscarnet, ganciclovir, valganciclovir, scyclovir within the last 7 days. 4.Known or suspected underlying immune deficiency [history of solid organ or stem cell transplantation, infection with the human immunodeficiency virus, hematological malignancy, use of immunosuppressive medication (more than 0.1 mg prednisone per kilo for more than 3 months, more than 75 mg prednisone per day for more than 1 week, or equivalent), chemotherapy/radiotherapy in the year before ICU admission, and any known humoral or cellular immune deficiency]. 5.Pregnancy. 6.Patients with surgical complications or trauma.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To study correlation of cytomegalovirus reactivation, associated viral loads and its impact on mortality among non-immuno compromised adult septic patients.Timepoint: At 4 weeks or ICU discharge, which ever is earlier. | — |
Secondary
| Measure | Time frame |
|---|---|
| Evaluation of role of cell mediated immune response in CMV reactivation and associated patient outcome.Timepoint: At the time of ICU discharge.;To study viral load kinetics among CMV reactivation critically ill patients.Timepoint: 3, 6 and 9 days after patient positive for CMV. | — |
Countries
India
Contacts
Public ContactDr Atul Garg
Sanjay Gandhi Post graduate Institute of Medical sciences
Outcome results
None listed